As of 2026-10-14, the EV/EBITDA ratio of Revance Therapeutics Inc (RVNC) is -4.67. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RVNC's latest enterprise value is 764.47 mil USD. RVNC's TTM EBITDA according to its financial statements is -163.87 mil USD. Dividing these 2 quantities gives us the above RVNC EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.3x - 11.3x | 8.9x |
| Forward P/E multiples | 11.1x - 15.2x | 13.5x |
| Fair Price | (21.13) - (21.44) | (21.25) |
| Upside | -678.9% - -687.5% | -682.3% |
| Date | EV/EBITDA |